Beta-adrenoceptor signaling pathways mediate cardiac pathological remodeling

Frontiers in Bioscience - Elite

Volumn 4 E, Issue 5, 2012, Pages 1625-1637

  Fu, Yongnan ^a   Xiao, Han ^b   Zhang, Youyi ^a  

^a PEKING UNIVERSITY THIRD HOSPITAL   (China)

^b NONE

Author keywords

Apoptosis; Beta adrenoceptors; Cardiac remodeling; Fibrosis; Hypertrophy; Molecular mechanism; Review; Signaling Pathway

Indexed keywords

ALPHA TROPOMYOSIN; ANGIOTENSIN II; ATRIAL NATRIURETIC FACTOR; BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; CALCINEURIN; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II; CYCLIC AMP DEPENDENT PROTEIN KINASE; DOBUTAMINE; ENDOTHELIN 1; GLYCOGEN SYNTHASE KINASE 3BETA; INTERLEUKIN 6; ISOPRENALINE; MAMMALIAN TARGET OF RAPAMYCIN; METOPROLOL; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE 6; MITOGEN ACTIVATED PROTEIN KINASE KINASE 7; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHATIDYLINOSITOL 3 KINASE; REACTIVE OXYGEN METABOLITE; S6 KINASE; SOMATOMEDIN C; STAT3 PROTEIN; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR NFAT; TRANSFORMING GROWTH FACTOR BETA1; BETA ADRENERGIC RECEPTOR;

ADRENERGIC STIMULATION; APOPTOSIS; AUTOCRINE EFFECT; CELL COMMUNICATION; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; COLLAGEN SYNTHESIS; DNA CONTENT; DOWN REGULATION; ENDOCYTOSIS; ENZYME ACTIVATION; EXCITATION CONTRACTION COUPLING; EXTRACELLULAR MATRIX; GENE OVEREXPRESSION; HEART FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE FIBROSIS; HUMAN; INTRACELLULAR SIGNALING; MITOCHONDRIAL MEMBRANE POTENTIAL; NONHUMAN; PARACRINE SIGNALING; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RECEPTOR DENSITY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; VASCULAR RESISTANCE; HEART MUSCLE; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION;

APOPTOSIS; HUMANS; MYOCARDIUM; RECEPTORS, ADRENERGIC, BETA; SIGNAL TRANSDUCTION;

EID: 84860855245     PISSN: 19450494     EISSN: 19450508     Source Type: Journal    
DOI: None     Document Type: Review

References (126)

1. D.B. Bylund, D.C. Eikenberg, J.P. Hieble, S.Z. Langer, R.J. Lefkowitz, K.P. Minneman, P.B. Molinoff, R.R. Ruffolo Jr and U. Trendelenburg: International Union of Pharmacology nomenclature of adrenoceptors. Pharmacol Rev 46, 121-136 (1994))
2. O.E. Brodde: Beta1-and beta2-adrenoceptors in the human heart: properties, function, and alterations in chronic heart failure. Pharmacol Rev 43, 203-242 (1991))
3. D.S. Feldman, C.A. Carnes, W.T. Abraham and M.R. Bristow: Mechanisms of disease: betaadrenergic receptors - alterations in signal transduction and pharmacogenomics in heart failure. Nat Clin Pract Cardiovasc Med 2, 475-483 (2005)) (Pubitemid 41223525)
4. B. Rozec and C. Gauthier: Beta3-adrenoceptors in the cardiovascular system: putative roles in human pathologies. Pharmacol Ther 111, 652-673 (2006)) (Pubitemid 44137382)
5. Y. Xiang and B.K. Kobilka: Myocyte adrenoceptor signaling pathways. Science 300, 1530-1532 (2003)) (Pubitemid 36682874)
6. A. Chesley, M.S. Lundberg, T. Asai, R.P. Xiao, S. Ohtani, E.G. Lakatta and M.T. Crow: The beta(2)- adrenergic receptor delivers an antiapoptotic signal to cardiac myocytes through G(i)-dependent coupling to phosphatidylinositol 3'-kinase. Circ Res 87, 1172-1179 (2000))
7. W. Zhu, X. Zeng, M. Zheng and R.P. Xiao: The enigma of beta2-adrenergic receptor Gi signaling in the heart: the good, the bad, and the ugly. Circ Res 97, 507-509 (2005)) (Pubitemid 41361739)
8. M. Zaugg, W. Xu, E. Lucchinetti, S.A. Shafiq, N.Z. Jamali and M.A. Siddiqui: Beta-adrenergic receptor subtypes differentially affect apoptosis in adult rat ventricular myocytes. Circulation 102, 344-350 (2000)) (Pubitemid 30457587)
9. M. Zheng, Q.D. Han and R.P. Xiao: Distinct betaadrenergic receptor subtype signaling in the heart and their pathophysiological relevance. Sheng Li Xue Bao 56, 1-15 (2004))
10. R.P. Xiao, X. Ji and E.G. Lakatta: Functional coupling of the beta 2-adrenoceptor to a pertussis toxin-sensitive G protein in cardiac myocytes. Mol Pharmacol 47, 322-329 (1995))
11. A. Kaumann, S. Bartel, P. Molenaar, L. Sanders, K. Burrell, D. Vetter, P. Hempel, P. Karczewski and E.G. Krause: Activation of beta2-adrenergic receptors hastens relaxation and mediates phosphorylation of phospholamban, troponin I, and C-protein in ventricular myocardium from patients with terminal heart failure. Circulation 99, 65-72 (1999)) (Pubitemid 29035959)
12. I.S. Anand, L.D. Fisher, Y.T. Chiang, R. Latini, S. Masson, A.P. Maggioni, R.D. Glazer, G. Tognoni and J.N. Cohn: Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation 107, 1278-1283 (2003)) (Pubitemid 36314411)
13. J.N. Cohn, R. Ferrari and N. Sharpe: Cardiac remodeling-concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling. J Am Coll Cardiol 35, 569-582 (2000)) (Pubitemid 30167013)
14. T. Aiba and G.F. Tomaselli: Electrical remodeling in the failing heart. Curr Opin Cardiol 25, 29-36 (2010))
15. M. Scoote and A.J. Williams: Myocardial calcium signalling and arrhythmia pathogenesis. Biochem Biophys Res Commun 322, 1286-1309 (2004)) (Pubitemid 39164658)
16. A.J. Workman: Cardiac adrenergic control and atrial fibrillation. Naunyn Schmiedebergs Arch Pharmacol 381, 235-249 (2010))
17. B.H. Lorell: Transition from hypertrophy to failure. Circulation 96, 3824-3827 (1997)) (Pubitemid 27506035)
18. N. Frey and E.N. Olson: Cardiac hypertrophy: the good, the bad, and the ugly. Annu Rev Physiol 65, 45-79 (2003)) (Pubitemid 38249147)
19. F. Waagstein, M.R. Bristow, K. Swedberg, F. Camerini, M.B. Fowler, M.A. Silver, E.M. Gilbert, M.R. Johnson, F.G. Goss and A. Hjalmarson: Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Lancet 342, 1441-1446 (1993)) (Pubitemid 24000287)
20. E.J. Eichhorn, C.M. Heesch, J.H. Barnett, L.G. Alvarez, S.M. Fass, P.A. Grayburn, B.A. Hatfield, L.G. Marcoux and C.R. Malloy: Effect of metoprolol on myocardial function and energetics in patients with nonischemic dilated cardiomyopathy: a randomized, double-blind, placebo-controlled study. J Am Coll Cardiol 24, 1310-1320 (1994)) (Pubitemid 24331872)
21. O.E. Osadchii: Cardiac hypertrophy induced by sustained beta-adrenoreceptor activation: pathophysiological aspects. Heart Fail Rev 12, 66-86 (2007)) (Pubitemid 46629248)
22. M. Anderson, D. Moore and D. Larson: Comparison of isoproterenol and dobutamine in the induction of cardiac hypertrophy and fibrosis. Perfusion 23, 231-235 (2008))
23. C. Morisco, D.C. Zebrowski, D.E. Vatner, S.F. Vatner and J. Sadoshima: Beta-adrenergic cardiac hypertrophy is mediated primarily by the beta(1)-subtype in the rat heart. J Mol Cell Cardiol 33, 561-573 (2001)) (Pubitemid 32539011)
24. J.D. Bisognano, H.D. Weinberger, T.J. Bohlmeyer, A. Pende, M.V. Raynolds, A. Sastravaha, R. Roden, K. Asano, B.C. Blaxall, S.C. Wu, C. Communal, K. Singh, W. Colucci, M.R. Bristow and D.J. Port: Myocardial-directed overexpression of the human beta(1)-adrenergic receptor in transgenic mice. J Mol Cell Cardiol 32, 817-830 (2000)) (Pubitemid 30658918)
25. G.W. Dorn 2nd, N.M. Tepe, J.N. Lorenz, W.J. Koch and S.B. Liggett: Low- and high-level transgenic expression of beta2-adrenergic receptors differentially affect cardiac hypertrophy and function in Galphaqoverexpressing mice. Proc Natl Acad Sci U S A 96, 6400-6405 (1999)) (Pubitemid 29256677)
26. Du XJ, D.J. Autelitano, R.J. Dilley, B. Wang, A.M. Dart and E.A. Woodcock: beta(2)-adrenergic receptor overexpression exacerbates development of heart failure after aortic stenosis. Circulation 101, 71-77 (2000)) (Pubitemid 30039079)
27. C. Gaudin, Y. Ishikawa, D.C. Wight, V. Mahdavi, B. Nadal-Ginard, T.E. Wagner, D.E. Vatner and C.J. Homcy: Overexpression of Gs alpha protein in the hearts of transgenic mice. J Clin Invest 95, 1676-1683 (1995))
28. C.L. Antos, N. Frey, S.O. Marx, S. Reiken, M. Gaburjakova, J.A. Richardson, A.R. Marks and E.N. Olson: Dilated cardiomyopathy and sudden death resulting from constitutive activation of protein kinase a. Circ Res 89, 997-1004 (2001)) (Pubitemid 34640866)
29. G. Lewin, M. Matus, A. Basu, K. Frebel, S.P. Rohsbach, A. Safronenko, M.D. Seidl, F. Stumpel, I. Buchwalow, S. Konig, S. Engelhardt, M.J. Lohse, W. Schmitz and F.U. Muller: Critical role of transcription factor cyclic AMP response element modulator in beta1- adrenoceptor-mediated cardiac dysfunction. Circulation 119, 79-88 (2009))
30. P.A. Watson, J.E. Reusch, S.A. McCune, L.A. Leinwand, S.W. Luckey, J.P. Konhilas, D.A. Brown, A.J. Chicco, G.C. Sparagna, C.S. Long and R.L. Moore: Restoration of CREB function is linked to completion and stabilization of adaptive cardiac hypertrophy in response to exercise. Am J Physiol Heart Circ Physiol 293, H246-259 (2007)) (Pubitemid 47105079)
31. C.A. Molina, N.S. Foulkes, E. Lalli and P. Sassone-Corsi: Inducibility and negative autoregulation of CREM: an alternative promoter directs the expression of ICER, an early response repressor. Cell 75, 875-886 (1993)) (Pubitemid 24014545)
32. E.J. Folco and G. Koren: Degradation of the inducible cAMP early repressor (ICER) by the ubiquitin-proteasome pathway. Biochem J 328 ( Pt 1), 37-43 (1997)) (Pubitemid 27499437)
33. H. Tomita, M. Nazmy, K. Kajimoto, G. Yehia, C.A. Molina and J. Sadoshima: Inducible cAMP early repressor (ICER) is a negative-feedback regulator of cardiac hypertrophy and an important mediator of cardiac myocyte apoptosis in response to beta-adrenergic receptor stimulation. Circ Res 93, 12-22 (2003)) (Pubitemid 36859036)
34. A. Sabri, E. Pak, S.A. Alcott, B.A. Wilson and S.F. Steinberg: Coupling function of endogenous alpha(1)- and beta-adrenergic receptors in mouse cardiomyocytes. Circ Res 86, 1047-1053 (2000)) (Pubitemid 30367863)
35. F. Yin, Y. Zhu, P. Li, Q.D. Han and Y.Y. Zhang: Isoproterenol-induced activation of MAPK, NFkappaB and JAK/STAT pathway in mouse myocardium. Sheng Li Xue Bao 55, 449-453 (2003)) (Pubitemid 37101604)
36. G.X. Zhang, S. Kimura, A. Nishiyama, T. Shokoji, M. Rahman, L. Yao, Y. Nagai, Y. Fujisawa, A. Miyatake and Y. Abe: Cardiac oxidative stress in acute and chronic isoproterenol-infused rats. Cardiovasc Res 65, 230-238 (2005)) (Pubitemid 40038496)
37. Y. Zou, I. Komuro, T. Yamazaki, S. Kudoh, H. Uozumi, T. Kadowaki and Y. Yazaki: Both Gs and Gi proteins are critically involved in isoproterenol-induced cardiomyocyte hypertrophy. J Biol Chem 274, 9760-9770 (1999))
38. M. Zheng, R. Hou, Q. Han and R.P. Xiao: Different regulation of ERK1/2 activation by beta-adrenergic receptor subtypes in adult mouse cardiomyocytes. Heart Lung Circ 13, 179-183 (2004)) (Pubitemid 38877990)
39. M. Zheng, S.J. Zhang, W.Z. Zhu, B. Ziman, B.K. Kobilka and R.P. Xiao: beta 2-adrenergic receptor-induced p38 MAPK activation is mediated by protein kinase A rather than by Gi or gbeta gamma in adult mouse cardiomyocytes. J Biol Chem 275, 40635-40640 (2000)) (Pubitemid 32064704)
40. A. Remondino, S.H. Kwon, C. Communal, D.R. Pimentel, D.B. Sawyer, K. Singh and W.S. Colucci: Beta-adrenergic receptor-stimulated apoptosis in cardiac myocytes is mediated by reactive oxygen species/c-Jun NH2-terminal kinasedependent activation of the mitochondrial pathway. Circ Res 92, 136-138 (2003)) (Pubitemid 36254269)
41. T. Noma, A. Lemaire, P.S.V. Naga, L. Barki-Harrington, D.G. Tilley, J. Chen, C.P. Le, J.D. Violin, H. Wei, R.J. Lefkowitz and H.A. Rockman: Beta-arrestin-mediated beta1- adrenergic receptor transactivation of the EGFR confers cardioprotection. J Clin Invest 117, 2445-2458 (2007))
42. K. Gong, Z. Li, M. Xu, Du J, Z. Lv and Y. Zhang: A novel protein kinase A-independent, beta-arrestin-1- dependent signaling pathway for p38 mitogen-activated protein kinase activation by beta2-adrenergic receptors. J Biol Chem 283, 29028-29036 (2008))
43. O.F. Bueno, De Windt LJ, K.M. Tymitz, S.A. Witt, T.R. Kimball, R. Klevitsky, T.E. Hewett, S.P. Jones, D.J. Lefer, C.F. Peng, R.N. Kitsis and J.D. Molkentin: The MEK1-ERK1/2 signaling pathway promotes compensated cardiac hypertrophy in transgenic mice. EMBO J 19, 6341-6350 (2000))
44. B. Sanna, O.F. Bueno, Y.S. Dai, B.J. Wilkins and J.D. Molkentin: Direct and indirect interactions between calcineurin-NFAT and MEK1-extracellular signalregulated kinase 1/2 signaling pathways regulate cardiac gene expression and cellular growth. Mol Cell Biol 25, 865-878 (2005)) (Pubitemid 40165796)
45. P. Liao, D. Georgakopoulos, A. Kovacs, M. Zheng, D. Lerner, H. Pu, J. Saffitz, K. Chien, R.P. Xiao, D.A. Kass and Y. Wang: The in vivo role of p38 MAP kinases in cardiac remodeling and restrictive cardiomyopathy. Proc Natl Acad Sci U S A 98, 12283-12288 (2001)) (Pubitemid 32959865)
46. P.S. Peter, J.E. Brady, L. Yan, W. Chen, S. Engelhardt, Y. Wang, J. Sadoshima, S.F. Vatner and D.E. Vatner: Inhibition of p38 alpha MAPK rescues cardiomyopathy induced by overexpressed beta 2-adrenergic receptor, but not beta 1-adrenergic receptor. J Clin Invest 117, 1335-1343 (2007)) (Pubitemid 46718421)
47. Y. Wang, B. Su, V.P. Sah, J.H. Brown, J. Han and K.R. Chien: Cardiac hypertrophy induced by mitogen-activated protein kinase kinase 7, a specific activator for c-Jun NH2- terminal kinase in ventricular muscle cells. J Biol Chem 273, 5423-5426 (1998)) (Pubitemid 28124000)
48. Q. Liang, O.F. Bueno, B.J. Wilkins, C.Y. Kuan, Y. Xia and J.D. Molkentin: c-Jun N-terminal kinases (JNK) antagonize cardiac growth through cross-talk with calcineurin-NFAT signaling. EMBO J 22, 5079-5089 (2003)) (Pubitemid 37222028)
49. J.D. Molkentin: Calcineurin-NFAT signaling regulates the cardiac hypertrophic response in coordination with the MAPKs. Cardiovasc Res 63, 467-475 (2004)) (Pubitemid 38970191)
50. C.F. Rossow, K.W. Dilly, C. Yuan, M. Nieves-Cintron, J.L. Cabarrus and L.F. Santana: NFATc3-dependent loss of I(to) gradient across the left ventricular wall during chronic beta adrenergic stimulation. J Mol Cell Cardiol 46, 249-256 (2009))
51. G.W. Dorn 2nd and T. Force: Protein kinase cascades in the regulation of cardiac hypertrophy. J Clin Invest 115, 527-537 (2005)) (Pubitemid 40322222)
52. T. Morimoto, K. Hasegawa, H. Wada, T. Kakita, S. Kaburagi, T. Yanazume and S. Sasayama: Calcineurin- GATA4 pathway is involved in beta-adrenergic agonistresponsive endothelin-1 transcription in cardiac myocytes. J Biol Chem 276, 34983-34989 (2001))
53. B. Yoo, A. Lemaire, S. Mangmool, M.J. Wolf, A. Curcio, L. Mao and H.A. Rockman: Beta1-adrenergic receptors stimulate cardiac contractility and CaMKII activation in vivo and enhance cardiac dysfunction following myocardial infarction. Am J Physiol Heart Circ Physiol 297, H1377-1386 (2009))
54. J.D. Molkentin, J.R. Lu, C.L. Antos, B. Markham, J. Richardson, J. Robbins, S.R. Grant and E.N. Olson: A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell 93, 215-228 (1998)) (Pubitemid 28180855)
55. N.N. Petrashevskaya, I. Bodi, M. Rubio, J.D. Molkentin and A. Schwartz: Cardiac function and electrical remodeling of the calcineurin-overexpressed transgenic mouse. Cardiovasc Res 54, 117-132 (2002)) (Pubitemid 34327942)
56. O.F. Bueno, B.J. Wilkins, K.M. Tymitz, B.J. Glascock, T.F. Kimball, J.N. Lorenz and J.D. Molkentin: Impaired cardiac hypertrophic response in Calcineurin Abeta - deficient mice. Proc Natl Acad Sci U S A 99, 4586-4591 (2002)) (Pubitemid 34286028)
57. De Windt LJ, H.W. Lim, O.F. Bueno, Q. Liang, U. Delling, J.C. Braz, B.J. Glascock, T.F. Kimball, M.F. del, R.J. Hajjar and J.D. Molkentin: Targeted inhibition of calcineurin attenuates cardiac hypertrophy in vivo. Proc Natl Acad Sci U S A 98, 3322-3327 (2001)) (Pubitemid 32220844)
58. L.C. Cantley: The phosphoinositide 3-kinase pathway. Science 296, 1655-1657 (2002)) (Pubitemid 34579158)
59. K.D. Schluter, Y. Goldberg, G. Taimor, M. Schafer and H.M. Piper: Role of phosphatidylinositol 3-kinase activation in the hypertrophic growth of adult ventricular cardiomyocytes. Cardiovasc Res 40, 174-181 (1998)) (Pubitemid 28435442)
60. W.Z. Zhu, M. Zheng, W.J. Koch, R.J. Lefkowitz, B.K. Kobilka and R.P. Xiao: Dual modulation of cell survival and cell death by beta(2)-adrenergic signaling in adult mouse cardiac myocytes. Proc Natl Acad Sci U S A 98, 1607-1612 (2001)) (Pubitemid 32165546)
61. D.S. Feldman, C.A. Carnes, W.T. Abraham and M.R. Bristow: Mechanisms of disease: beta-adrenergic receptors- -alterations in signal transduction and pharmacogenomics in heart failure. Nat Clin Pract Cardiovasc Med 2, 475-483 (2005)) (Pubitemid 41223525)
62. D.S. Feldman, T.S. Elton, B. Sun, M.M. Martin and M.T. Ziolo: Mechanisms of disease: detrimental adrenergic signaling in acute decompensated heart failure. Nat Clin Pract Cardiovasc Med 5, 208-218 (2008)) (Pubitemid 351472165)
63. B. DeBosch, I. Treskov, T.S. Lupu, C. Weinheimer, A. Kovacs, M. Courtois and A.J. Muslin: Akt1 is required for physiological cardiac growth. Circulation 113, 2097-2104 (2006))
64. T. Shioi, P.M. Kang, P.S. Douglas, J. Hampe, C.M. Yballe, J. Lawitts, L.C. Cantley and S. Izumo: The conserved phosphoinositide 3-kinase pathway determines heart size in mice. EMBO J 19, 2537-2548 (2000)) (Pubitemid 30323543)
65. J.R. McMullen, T. Shioi, L. Zhang, O. Tarnavski, M.C. Sherwood, P.M. Kang and S. Izumo: Phosphoinositide 3- kinase(p110alpha) plays a critical role for the induction of physiological, but not pathological, cardiac hypertrophy. Proc Natl Acad Sci U S A 100, 12355-12360 (2003)) (Pubitemid 37271564)
66. G.Y. Oudit, M.A. Crackower, U. Eriksson, R. Sarao, I. Kozieradzki, T. Sasaki, J. Irie-Sasaki, D. Gidrewicz, V.O. Rybin, T. Wada, S.F. Steinberg, P.H. Backx and J.M. Penninger: Phosphoinositide 3-kinase gamma-deficient mice are protected from isoproterenol-induced heart failure. Circulation 108, 2147-2152 (2003)) (Pubitemid 37337593)
67. S.V. Naga Prasad, G. Esposito, L. Mao, W.J. Koch and H.A. Rockman: Gbetagamma-dependent phosphoinositide 3-kinase activation in hearts with in vivo pressure overload hypertrophy. J Biol Chem 275, 4693-4698 (2000)) (Pubitemid 30108856)
68. E. Patrucco, A. Notte, L. Barberis, G. Selvetella, A. Maffei, M. Brancaccio, S. Marengo, G. Russo, O. Azzolino, S.D. Rybalkin, L. Silengo, F. Altruda, R. Wetzker, M.P. Wymann, G. Lembo and E. Hirsch: PI3Kgamma modulates the cardiac response to chronic pressure overload by distinct kinase-dependent and - independent effects. Cell 118, 375-387 (2004). (Pubitemid 39061117)
69. B. Vanhaesebroeck, S.J. Leevers, K. Ahmadi, J. Timms, R. Katso, P.C. Driscoll, R. Woscholski, P.J. Parker and M.D. Waterfield: Synthesis and function of 3- phosphorylated inositol lipids. Annu Rev Biochem 70, 535-602 (2001)) (Pubitemid 32662219)
70. M.P. Wymann, M. Zvelebil and M. Laffargue: Phosphoinositide 3-kinase signalling - which way to target. Trends Pharmacol Sci 24, 366-376 (2003)) (Pubitemid 37315529)
71. J.J. Nienaber, H. Tachibana, P.S.V. Naga, G. Esposito, D. Wu, L. Mao and H.A. Rockman: Inhibition of receptorlocalized PI3K preserves cardiac beta-adrenergic receptor function and ameliorates pressure overload heart failure. J Clin Invest 112, 1067-1079 (2003)) (Pubitemid 38056322)
72. J.C. Ferreira, A.V. Bacurau, F.S. Evangelista, M.A. Coelho, E.M. Oliveira, D.E. Casarini, J.E. Krieger and P.C. Brum: The role of local and systemic renin angiotensin system activation in a genetic model of sympathetic hyperactivity-induced heart failure in mice. Am J Physiol Regul Integr Comp Physiol 294, R26-32 (2008))
73. F. Yin, P. Li, M. Zheng, L. Chen, Q. Xu, K. Chen, Y.Y. Wang, Y.Y. Zhang and C. Han: Interleukin-6 family of cytokines mediates isoproterenol-induced delayed STAT3 activation in mouse heart. J Biol Chem 278, 21070-21075 (2003)) (Pubitemid 36806418)
74. F. Yin, Y.Y. Wang, Du JH, C. Li, Z.Z. Lu, C. Han and Y.Y. Zhang: Noncanonical cAMP pathway and p38 MAPK mediate beta2-adrenergic receptor-induced IL-6 production in neonatal mouse cardiac fibroblasts. J Mol Cell Cardiol 40, 384-393 (2006)) (Pubitemid 43277840)
75. D.E. Dostal: The cardiac renin-angiotensin system: novel signaling mechanisms related to cardiac growth and function. Regul Pept 91, 1-11 (2000))
76. F.H. Leenen, R. White and B. Yuan: Isoproterenolinduced cardiac hypertrophy: role of circulatory versus cardiac renin-angiotensin system. Am J Physiol Heart Circ Physiol 281, H2410-2416 (2001))
77. Y. Matsui, N. Jia, H. Okamoto, S. Kon, H. Onozuka, M. Akino, L. Liu, J. Morimoto, S.R. Rittling, D. Denhardt, A. Kitabatake and T. Uede: Role of osteopontin in cardiac fibrosis and remodeling in angiotensin II-induced cardiac hypertrophy. Hypertension 43, 1195-1201 (2004)) (Pubitemid 38691740)
78. L.J. Heller, J.A. Opsahl, S.E. Wernsing, R. Saxena and S.A. Katz: Myocardial and plasma renin-angiotensinogen dynamics during pressure-induced cardiac hypertrophy. Am J Physiol 274, R849-856 (1998))
79. R.N. Re: Mechanisms of disease: local reninangiotensin- aldosterone systems and the pathogenesis and treatment of cardiovascular disease. Nat Clin Pract Cardiovasc Med 1, 42-47 (2004)) (Pubitemid 40823721)
80. V.C. Busatto, V. Cunha, M.A. Cicilini and J.G. Mill: Differential effects of isoproterenol on the activity of angiotensin-converting enzyme in the rat heart and aorta. Braz J Med Biol Res 32, 355-360 (1999))
81. J.C. Ferreira, A.V. Bacurau, F.S. Evangelista, M.A. Coelho, E.M. Oliveira, D.E. Casarini, J.E. Krieger and P.C. Brum: The role of local and systemic renin angiotensin system activation in a genetic model of sympathetic hyperactivity-induced heart failure in mice. Am J Physiol Regul Integr Comp Physiol 294, R26-32 (2008))
82. T. Tsutamoto, T. Hisanaga, A. Wada, K. Maeda, M. Ohnishi, D. Fukai, N. Mabuchi, M. Sawaki and M. Kinoshita: Interleukin-6 spillover in the peripheral circulation increases with the severity of heart failure, and the high plasma level of interleukin-6 is an important prognostic predictor in patients with congestive heart failure. J Am Coll Cardiol 31, 391-398 (1998)) (Pubitemid 28153460)
83. K. Kunisada, E. Tone, Y. Fujio, H. Matsui, K. Yamauchi-Takihara and T. Kishimoto: Activation of gp130 transduces hypertrophic signals via STAT3 in cardiac myocytes. Circulation 98, 346-352 (1998)) (Pubitemid 28348057)
84. H. Zhang, W. Feng, W. Liao, X. Ma, Q. Han and Y. Zhang: The gp130/STAT3 signaling pathway mediates beta-adrenergic receptor-induced atrial natriuretic factor expression in cardiomyocytes. FEBS J 275, 3590-3597 (2008))
85. N. Szabo-Fresnais, F. Lefebvre, A. Germain, R. Fischmeister and M. Pomerance: A new regulation of IL-6 production in adult cardiomyocytes by beta-adrenergic and IL-1 beta receptors and induction of cellular hypertrophy by IL-6 trans-signalling. Cell Signal 22, 1143-1152 (2010))
86. J.L. Bos: Epac proteins: multi-purpose cAMP targets. Trends Biochem Sci 31, 680-686 (2006)) (Pubitemid 44791945)
87. E. Morel, A. Marcantoni, M. Gastineau, R. Birkedal, F. Rochais, A. Garnier, A.M. Lompre, G. Vandecasteele and F. Lezoualc'h: cAMP-binding protein Epac induces cardiomyocyte hypertrophy. Circ Res 97, 1296-1304 (2005))
88. M. Metrich, A. Lucas, M. Gastineau, J.L. Samuel, C. Heymes, E. Morel and F. Lezoualc'h: Epac mediates betaadrenergic receptor-induced cardiomyocyte hypertrophy. Circ Res 102, 959-965 (2008)) (Pubitemid 351591548)
89. P.A. Patel, D.G. Tilley and H.A. Rockman: Betaarrestin- mediated signaling in the heart. Circ J 72, 1725-1729 (2008))
90. C. Morisco, C. Marrone, J. Galeotti, D. Shao, D.E. Vatner, S.F. Vatner and J. Sadoshima: Endocytosis machinery is required for beta1-adrenergic receptorinduced hypertrophy in neonatal rat cardiac myocytes. Cardiovasc Res 78, 36-44 (2008)) (Pubitemid 351430961)
91. F. Yin, Z.Z. Lu, Q.D. Han and Y.Y. Zhang: Expression of beta2-adrenergic receptor and its effect on the proliferation of neonatal rat cardiac fibroblasts. Sheng Li Xue Bao 55, 251-254 (2003)) (Pubitemid 36958824)
92. A.B. Gustafsson and L.L. Brunton: beta-adrenergic stimulation of rat cardiac fibroblasts enhances induction of nitric-oxide synthase by interleukin-1beta via message stabilization. Mol Pharmacol 58, 1470-1478 (2000))
93. N.A. Turner, K.E. Porter, W.H. Smith, H.L. White, S.G. Ball and A.J. Balmforth: Chronic beta2-adrenergic receptor stimulation increases proliferation of human cardiac fibroblasts via an autocrine mechanism. Cardiovasc Res 57, 784-792 (2003)) (Pubitemid 36254872)
94. N.A. Turner, D.J. O'regan, S.G. Ball and K.E. Porter: Endothelin-1 is an essential co-factor for beta2-adrenergic receptor-induced proliferation of human cardiac fibroblasts. FEBS Lett 576, 156-160 (2004)) (Pubitemid 39330475)
95. X. Liu, S.Q. Sun, A. Hassid and R.S. Ostrom: cAMP inhibits transforming growth factor-beta-stimulated collagen synthesis via inhibition of extracellular signalregulated kinase 1/2 and Smad signaling in cardiac fibroblasts. Mol Pharmacol 70, 1992-2003 (2006)) (Pubitemid 44771915)
96. G.C. Fan, Q. Yuan, G. Song, Y. Wang, G. Chen, J. Qian, X. Zhou, Y.J. Lee, M. Ashraf and E.G. Kranias: Small heat-shock protein Hsp20 attenuates beta-agonistmediated cardiac remodeling through apoptosis signalregulating kinase 1. Circ Res 99, 1233-1242 (2006)) (Pubitemid 44808660)
97. M. Gibbs, D.G. Veliotes, C. Anamourlis, D. Badenhorst, O. Osadchii, G.R. Norton and A.J. Woodiwiss: Chronic beta-adrenoreceptor activation increases cardiac cavity size through chamber remodeling and not via modifications in myocardial material properties. Am J Physiol Heart Circ Physiol 287, H2762-2767 (2004)) (Pubitemid 39557150)
98. S. Nakatsuji, J. Yamate, M. Kuwamura, T. Kotani and S. Sakuma: In vivo responses of macrophages and myofibroblasts in the healing following isoproterenolinduced myocardial injury in rats. Virchows Arch 430, 63-69 (1997)) (Pubitemid 27073308)
99. I.J. Benjamin, J.E. Jalil, L.B. Tan, K. Cho, K.T. Weber and W.A. Clark: Isoproterenol-induced myocardial fibrosis in relation to myocyte necrosis. Circ Res 65, 657-670 (1989)) (Pubitemid 19226442)
100. I. Ahmet, M. Krawczyk, W. Zhu, A.Y. Woo, C. Morrell, S. Poosala, R.P. Xiao, E.G. Lakatta and M.I. Talan: Cardioprotective and survival benefits of long-term combined therapy with beta2 adrenoreceptor (AR) agonist and beta1 AR blocker in dilated cardiomyopathy postmyocardial infarction. J Pharmacol Exp Ther 325, 491-499 (2008)) (Pubitemid 351574789)
101. G.K. Soppa, J. Lee, M.A. Stagg, L.E. Felkin, P.J. Barton, U. Siedlecka, S. Youssef, M.H. Yacoub and C.M. Terracciano: Role and possible mechanisms of clenbuterol in enhancing reverse remodelling during mechanical unloading in murine heart failure. Cardiovasc Res 77, 695-706 (2008)) (Pubitemid 351301875)
102. G. Taimor, K.D. Schluter, K. Frischkopf, M. Flesch, S. Rosenkranz and H.M. Piper: Autocrine regulation of TGF beta expression in adult cardiomyocytes. J Mol Cell Cardiol 31, 2127-2136 (1999)) (Pubitemid 30029024)
103. S. Motte, K. McEntee and R. Naeije: Endothelin receptor antagonists. Pharmacol Ther 110, 386-414 (2006))
104. P. Kohl, P. Camelliti, F.L. Burton and G.L. Smith: Electrical coupling of fibroblasts and myocytes: relevance for cardiac propagation. J Electrocardiol 38, 45-50 (2005)) (Pubitemid 41436486)
105. D.E. Vatner, G.P. Yang, Y.J. Geng, K. Asai, J.S. Yun, T.E. Wagner, Y. Ishikawa, S.P. Bishop, C.J. Homcy and S.F. Vatner: Determinants of the cardiomyopathic phenotype in chimeric mice overexpressing cardiac Gsalpha. Circ Res 86, 802-806 (2000)) (Pubitemid 30217830)
106. I. Banerjee, K. Yekkala, T.K. Borg and T.A. Baudino: Dynamic interactions between myocytes, fibroblasts, and extracellular matrix. Ann N Y Acad Sci 1080, 76-84 (2006)) (Pubitemid 44955414)
107. E. Iwai-Kanai and K. Hasegawa: Intracellular signaling pathways for norepinephrine- and endothelin-1- mediated regulation of myocardial cell apoptosis. Mol Cell Biochem 259, 163-168 (2004)) (Pubitemid 38523294)
108. E. Iwai-Kanai, K. Hasegawa, M. Araki, T. Kakita, T. Morimoto and S. Sasayama: alpha- and beta-adrenergic pathways differentially regulate cell type-specific apoptosis in rat cardiac myocytes. Circulation 100, 305-311 (1999)) (Pubitemid 29340139)
109. S. Engelhardt, L. Hein, F. Wiesmann and M.J. Lohse: Progressive hypertrophy and heart failure in beta1- adrenergic receptor transgenic mice. Proc Natl Acad Sci U S A 96, 7059-7064 (1999)) (Pubitemid 29275009)
110. M. Iwase, S.P. Bishop, M. Uechi, D.E. Vatner, R.P. Shannon, R.K. Kudej, D.C. Wight, T.E. Wagner, Y. Ishikawa, C.J. Homcy and S.F. Vatner: Adverse effects of chronic endogenous sympathetic drive induced by cardiac GS alpha overexpression. Circ Res 78, 517-524 (1996))
111. M. Ito, T. Adachi, D.R. Pimentel, Y. Ido and W.S. Colucci: Statins inhibit beta-adrenergic receptor-stimulated apoptosis in adult rat ventricular myocytes via a Rac1- dependent mechanism. Circulation 110, 412-418 (2004)) (Pubitemid 38993850)
112. H. Nakayama, X. Chen, C.P. Baines, R. Klevitsky, X. Zhang, H. Zhang, N. Jaleel, B.H. Chua, T.E. Hewett, J. Robbins, S.R. Houser and J.D. Molkentin: Ca2+- and mitochondrial-dependent cardiomyocyte necrosis as a primary mediator of heart failure. J Clin Invest 117, 2431-2444 (2007)) (Pubitemid 47494345)
113. W.Z. Zhu, S.Q. Wang, K. Chakir, D. Yang, T. Zhang, J.H. Brown, E. Devic, B.K. Kobilka, H. Cheng and R.P. Xiao: Linkage of beta1-adrenergic stimulation to apoptotic heart cell death through protein kinase A-independent activation of Ca2+/calmodulin kinase II. J Clin Invest 111, 617-625 (2003)) (Pubitemid 36278580)
114. W. Zhu, A.Y. Woo, D. Yang, H. Cheng, M.T. Crow and R.P. Xiao: Activation of CaMKIIdeltaC is a common intermediate of diverse death stimuli-induced heart muscle cell apoptosis. J Biol Chem 282, 10833-10839 (2007)) (Pubitemid 47093465)
115. R. Zhang, M.S. Khoo, Y. Wu, Y. Yang, C.E. Grueter, G. Ni, E.E. Price Jr, W. Thiel, S. Guatimosim, L.S. Song, E.C. Madu, A.N. Shah, T.A. Vishnivetskaya, J.B. Atkinson, V.V. Gurevich, G. Salama, W.J. Lederer, R.J. Colbran and M.E. Anderson: Calmodulin kinase II inhibition protects against structural heart disease. Nat Med 11, 409-417 (2005)) (Pubitemid 40562331)
116. Y. Yang, W.Z. Zhu, M.L. Joiner, R. Zhang, C.V. Oddis, Y. Hou, J. Yang, E.E. Price, L. Gleaves, M. Eren, G. Ni, D.E. Vaughan, R.P. Xiao and M.E. Anderson: Calmodulin kinase II inhibition protects against myocardial cell apoptosis in vivo. Am J Physiol Heart Circ Physiol 291, H3065-3075 (2006)) (Pubitemid 44904109)
117. S. Saito, Y. Hiroi, Y. Zou, R. Aikawa, H. Toko, F. Shibasaki, Y. Yazaki, R. Nagai and I. Komuro: beta- Adrenergic pathway induces apoptosis through calcineurin activation in cardiac myocytes. J Biol Chem 275, 34528-34533 (2000))
118. L.J. De Windt, H.W. Lim, T. Taigen, D. Wencker, G. Condorelli, G.W. Dorn 2nd, R.N. Kitsis and J.D. Molkentin: Calcineurin-mediated hypertrophy protects cardiomyocytes from apoptosis in vitro and in vivo: An apoptosis-independent model of dilated heart failure. Circ Res 86, 255-263 (2000)) (Pubitemid 30108817)
119. T. Kakita, K. Hasegawa, E. Iwai-Kanai, S. Adachi, T. Morimoto, H. Wada, T. Kawamura, T. Yanazume and S. Sasayama: Calcineurin pathway is required for endothelin- 1-mediated protection against oxidant stress-induced apoptosis in cardiac myocytes. Circ Res 88, 1239-1246 (2001)) (Pubitemid 32587839)
120. B. Menon, M. Singh and K. Singh: Matrix metalloproteinases mediate beta-adrenergic receptorstimulated apoptosis in adult rat ventricular myocytes. Am J Physiol Cell Physiol 289, C168-176 (2005)) (Pubitemid 40880837)
121. C. Communal, M. Singh, B. Menon, Z. Xie, W.S. Colucci and K. Singh: beta1 integrins expression in adult rat ventricular myocytes and its role in the regulation of beta-adrenergic receptor-stimulated apoptosis. J Cell Biochem 89, 381-388 (2003)) (Pubitemid 36547272)
122. P. Krishnamurthy, V. Subramanian, M. Singh and K. Singh: Beta1 integrins modulate beta-adrenergic receptorstimulated cardiac myocyte apoptosis and myocardial remodeling. Hypertension 49, 865-872 (2007)) (Pubitemid 351664231)
123. B. Menon, M. Singh, R.S. Ross, J.N. Johnson and K. Singh: beta-Adrenergic receptor-stimulated apoptosis in adult cardiac myocytes involves MMP-2-mediated disruption of beta1 integrin signaling and mitochondrial pathway. Am J Physiol Cell Physiol 290, C254-261 (2006))
124. E.C. Goldsmith, W. Carver, A. McFadden, J.G. Goldsmith, R.L. Price, M. Sussman, B.H. Lorell, G. Cooper and T.K. Borg: Integrin shedding as a mechanism of cellular adaptation during cardiac growth. Am J Physiol Heart Circ Physiol 284, H2227-2234 (2003)) (Pubitemid 36622435)
125. B. Menon, J.N. Johnson, R.S. Ross, M. Singh and K. Singh: Glycogen synthase kinase-3beta plays a proapoptotic role in beta-adrenergic receptor-stimulated apoptosis in adult rat ventricular myocytes: Role of beta1 integrins. J Mol Cell Cardiol 42, 653-661 (2007)) (Pubitemid 46349131)
126. M. Singh, M. Roginskaya, S. Dalal, B. Menon, E. Kaverina, M.O. Boluyt and K. Singh: Extracellular ubiquitin inhibits beta-AR-stimulated apoptosis in cardiac myocytes: role of GSK-3beta and mitochondrial pathways. Cardiovasc Res 86, 20-28 (2010))